The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Open accessAbstract
Purpose: To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors. Recommendations: Based on results from multiple large randomized trials, adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Neither the optimal timing nor duration of aromatase inhibitor therapy is established. Aromatase inhibitors are appropriate as initial treatment for women with contraindications to tamoxifen. For all other postmenopausal women, treatment options include 5 years of aromatase inhibitors treatment or sequential therapy consisting of tamoxifen (for either 2 to 3 years or 5 years) followed by aromatase inhibitors for 2 to 3, or 5 years. Patients intolerant of aromatase inhibitors should receive tamoxifen. There are no data on the use of tamoxifen after an aromatase inhibitor in the adjuvant setting. Women with hormone receptor–negative tumors should not receive adjuvant endocrine therapy. The role of other biomarkers such as progesterone receptor and HER2 status in selecting optimal endocrine therapy remains controversial. Aromatase inhibitors are contraindicated in premenopausal women; there are limited data concerning their role in women with treatment-related amenorrhea. The side effect profiles of tamoxifen and aromatase inhibitors differ. The late consequences of aromatase inhibitor therapy, including osteoporosis, are not well characterized. Conclusion: The Panel believes that optimal adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen. Women with breast cancer and their physicians must weigh the risks and benefits of all therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Self-citationCoombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Self-citationThe ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861
Self-citationBonneterre, J., Thürlimann, B., Robertson, J. F. R., Krzakowski, M., Mauriac, L., Koralewski, P., Vergote, I., Webster, A., Steinberg, M., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3748 · Cited by 842
Mitwally, M. F. M., & Casper, R. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01705-2 · Cited by 800
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Fisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.684 · Cited by 635
Self-citationRisk of Menopause During the First Year After Breast Cancer Diagnosis
Goodwin, P. J., Ennis, M., Pritchard, K. I., Trudeau, M., & Hood, N. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2365 · Cited by 606
Self-citationGeisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.751 · Cited by 604
Bonneterre, J., Buzdar, A., Nabholtz, J.-M. A., Robertson, J. F. R., Th�rlimann, B., von Euler, M., Sahmoud, T., Webster, A., Steinberg, M., & Arimidex Writing Committee on behalf of the Investigators Committee Members (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2247::aid-cncr1570>3.0.co;2-y · Cited by 574
Ovarian ablation in early breast cancer: overview of the randomised trials
(1996) · The Lancet · doi:10.1016/s0140-6736(96)05023-4 · Cited by 561
The components of excess mortality after hip fracture
Kanis, J. A., Oden, A., Johnell, O., De Laet, C., Jonsson, B., & Oglesby, A. K. (2003) · Bone · doi:10.1016/s8756-3282(03)00061-9 · Cited by 549
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 521
Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2702 · Cited by 407
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3357 · Cited by 365
Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale
U.S. Preventive Services Task Force* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-6-200209170-00014 · Cited by 344
Tamoxifen for Prevention of Breast Cancer
Cersosimo, R. J. (2003) · Annals of Pharmacotherapy · doi:10.1177/106002800303700219 · Cited by 343
Meta-analysis of vascular and neoplastic events associated with tamoxifen
Braithwaite, R. S., Chlebowski, R. T., Lau, J., George, S., Hess, R., & Col, N. F. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.20724.x · Cited by 338
Self-citationGeisler, J., King, N. C., Anker, G. B., Ornati, G., di Salle, E., Lønning, P. E., & Dowsett, M. (1998) · PubMed · Cited by 314
Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer
Goss, P. E., & Strasser, K. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.881 · Cited by 298
Delmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.955 · Cited by 278
Saarto, T., Blomqvist, C., Välimäki, M., Mäkelä, P., Sarna, S., & Elomaa, I. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1341 · Cited by 265
Jonat, W., Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00014-3 · Cited by 254
Primary Care for Survivors of Breast Cancer
Burstein, H. J., & Winer, E. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010123431506 · Cited by 241
Self-citationSerum Estradiol Level and Risk of Breast Cancer During Treatment With Raloxifene
Cummings, S. R. (2002) · JAMA · doi:10.1001/jama.287.2.216 · Cited by 219
Buzdar, A. U., Jones, S. E., Vogel, C. L., Wolter, J., Plourde, P., Webster, A., & for the Arimidex Study Group (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<730::aid-cncr10>3.0.co;2-0 · Cited by 207
Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.020 · Cited by 200
Self-citationChlebowski, R. T., Col, N., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G., Burstein, H. J., Eisen, A., Lipkus, I., & Pfister, D. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.029 · Cited by 197
Self-citationSCOTTISHCANCERTRIALSBREASTGROU (1993) · The Lancet · doi:10.1016/0140-6736(93)90812-u · Cited by 191
Berry, D. A., Muss, H. B., Thor, A. D., Dressler, L., Liu, E. T., Broadwater, G., Budman, D. R., Henderson, I. C., Barcos, M., Hayes, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3471 · Cited by 180
Jordan, V. C., Gapstur, S., & Morrow, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.19.1449 · Cited by 169
Chlebowski, R. T., Collyar, D. E., Somerfield, M. R., & Pfister, D. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1939 · Cited by 164
Self-citationMinton, S. E., & Münster, P. N. (2002) · Cancer Control · doi:10.1177/107327480200900603 · Cited by 153
Paridaens, R., Therasse, P., Dirix, L. Y., Beex, L. V. A. M., Piccart, M. J., Cameron, D., Cufer, T., Roozendaal, K. J., Nooij, M. A., & Mattiacci, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.515 · Cited by 114
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
Fernö, M., Stål, O., Baldetrop, B., Hatschek, T., Källström, A.-C., Malmström, P., Nordenskjöld, B. A., & Rydén, S. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006332423620 · Cited by 94
Thurlimann, B. J. K., Robertson, J. F. R., Nabholtz, J., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00602-6 · Cited by 89
Boccardo, F., RUBAGOTTI, A., AMOROSO, D., Mesiti, M., Romeo, D., Caroti, C., Farris, A., Cruciani, G., Villa, E., Schieppati, G., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4209 · Cited by 82
Dowsett, M., Stein, R. C., & Coombes, R. C. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90201-s · Cited by 81
Winer, E. P., Hudis, C. A., Burstein, H. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.596 · Cited by 80
Self-citationAdaptive Hypersensitivity to Estrogen
Santen, R. J., Song, R. X.-D., Zhang, Z., Yue, W., & Kumar, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031207 · Cited by 75
Jakesz, R., Hausmaninger, H., Samonigg, H., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)80701-1 · Cited by 72
Loprinzi, C. L., Zahasky, K. M., Sloan, J. A., Novotny, P., & Quella, S. K. (2000) · Clinical Breast Cancer · doi:10.3816/cbc.2000.n.004 · Cited by 66
Saarto, T., Vehmanen, L., Elomaa, I., Välimäki, M., Mäkelä, P. M., & BLOMQVIST, C. P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1729 · Cited by 50
Stewart, H. (1992) · PubMed · Cited by 49
Dowsett, M., Doody, D., Miall, S., Howes, A. J., English, J., & Coombes, R. C. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006289811540 · Cited by 46
Ovarian Ablation as Adjuvant Therapy for Breast Cancer
Davidson, N. E. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003464 · Cited by 44
Jones, A., Powles, T., Law, M. G., et al. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1547 · Cited by 35
Self-citationChlebowski, R. T., Kim, J. A., & Col, N. F. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.021 · Cited by 28
Self-citationLønning, P. E., Geisler, J., Krag, L. E., Ottestad, L., Bremnes, Y., Hagen, A. I., Schlichting, E., Polli, A., Paolini, J., & Massimini, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.518 · Cited by 27
Cheung, K., Forward, D. P., Jackson, L., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)80055-1 · Cited by 12
Cited by
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationGoss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Self-citationA Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Metadata
- Authors
- Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., Cobleigh, M. A., Mamounas, E. P., Goldstein, L. J., Whelan, T. J., Powles, T. J., Bryant, J., Perkins, C., Perotti, J., Braun, S., Langer, A. S., Browman, G. P., & Somerfield, M. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-01-20
- Volume
- 23
- Issue
- 3
- Pages
- 619-629
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2151447010
- Cited by
- 1,031
- References
- 61
- FWCI
- 49.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.